1. Defining opportunistic invasive fungal infections in immunocompromised patients with cancer and hematopoietic stem cell transplants: An international consensus;Ascioglu;Clin Infect Dis,2002
2. Amphotericin B versus amphotericin B plus 5-fluorocytosine: poor results in the treatment of proven systemic mycoses in neutropenic patients;Verweij;Infection,1994
3. Liposomal amphotericin B compared with amphotericin B deoxycholate in the treatment of documented and suspected neutropenia-associated invasive fungal infections;Leenders;Brit J Haematol,1998
4. An EORTC International multicenter randomized trial (EORTC Number 19923) comparing two dosages of liposomal amphotericin B for treatment of invasive aspergillosis;Ellis;Clin Infect Dis,1998
5. A double-blind, randomized, controlled trial of amphotericin B colloidal dispersion versus amphotericin B for treatment of invasive aspergillosis in immunocompromised patients;Bowden;Clin Infect Dis,2002